Related Experiment Video
Updated: May 27, 2026
Cholesterol Efflux Assay
Published on: March 6, 2012
Effect of rosuvastatin treatment on cholesterol efflux from human macrophages
Ivana Kralova Lesna1, Vera Adamkova, Libuse Pagacova
1Institute for Clinical and Experimental Medicine, Prague, Czech Republic. ivka@ikem.cz
Insights
Rosuvastatin increases HDL cholesterol, but not necessarily cholesterol efflux. However, individual increases in HDL-C levels did correlate with improved cholesterol efflux from macrophages.
Area of Science:
- Cardiovascular Pharmacology
- Lipid Metabolism Research
Background:
- High-density lipoprotein cholesterol (HDL-C) increase is a known effect of statins like rosuvastatin.
- The direct impact of statin-induced HDL-C changes on reverse cholesterol transport (RCT) remains incompletely understood.
- Cholesterol efflux (CHE) is a critical step in RCT, influencing its overall rate.
Purpose of the Study:
- To investigate how rosuvastatin-induced changes in HDL-C affect cholesterol efflux (CHE).
- To analyze the relationship between altered HDL-C levels and the rate of CHE in patients with mixed dyslipidemia.
Main Methods:
- A study involving 14 participants with mixed dyslipidemia receiving 20 mg of rosuvastatin daily for 3 months.
- Measurement of CHE using 14C cholesterol-labeled macrophages before and after rosuvastatin treatment.
- Assessment of lipid metabolism parameters, including HDL-C and apolipoprotein levels.
Main Results:
- Rosuvastatin significantly reduced total cholesterol, LDL cholesterol, and apolipoprotein B, while increasing HDL-C (1.43 to 1.52 mmol/l).
- Apolipoprotein A1 levels remained unchanged, and there was no statistically significant overall increase in CHE (16.1% to 17.6%).
- A significant positive correlation was observed between individual changes in HDL-C and individual changes in CHE (r=0.76, p<0.05).
Conclusions:
- Rosuvastatin effectively increases HDL-C levels in patients with mixed dyslipidemia.
- While overall CHE did not significantly increase, individual variations in HDL-C levels were directly associated with corresponding individual changes in CHE.
- This suggests that rosuvastatin's impact on RCT may be more nuanced, with individual responses in HDL-C correlating with functional changes in cholesterol efflux.
Objectives:
One of the positive effects of rosuvastatin is an increase in HDL cholesterol (HDL-C). An increase in HDL-C is considered as one of the positive effects of this type of statin, although it does not necessarily correspond to the actual reverse cholesterol transport (RCT) rate. We analyzed the influence of statin induced changes in HDL-C on cholesterol efflux (CHE), the key step affecting the RCT.
Design:
Fourteen subjects (7 men, age: 50.9 ± 8.4 years and 7 women, age: 59.7 ± 10.6 years) with mixed dyslipidemia received 20 mg of rosuvastatin daily for 3 months. Before the initiation of statin therapy and at the end of the study period, the CHE from 14C cholesterol-labeled macrophages was determined in addition to parameters related to lipid metabolism. CHE was calculated as the percentage of radioactivity released from the macrophages into the media containing 5% of the examined plasma.
Results:
The rosuvastatin administration resulted in significant reductions of total cholesterol, LDL cholesterol, and apolipoprotein B and a significant increase in HDL-C (from 1.43 mmol/l to 1.52 mmol/l, p=0.05), while the levels of apolipoprotein A1 remained unchanged. There was no significant increase in CHE (from 16.1% to 17.6%, p for trend = 0.053). Individual changes in HDL-C correlated significantly (p<0.05) with individual changes of CHE (r=0.76).
Conclusion:
Administration of rosuvastatin increases HDL-C, and individual changes correlate with the individual increases of CHE from macrophages.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:29Cholesterol: Significance and Regulation
Considering cholesterol and...